CV Sciences, Inc.
CVSI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CVSI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CVSI
CV Sciences, Inc. is a biotechnology company focused on drug development and commercialization, with a current emphasis on cost reduction and capital raising to address a significant accumulated deficit and negative cash flow from operations.
Key risk: Going concern risk
BioSniper Score
Based on 4 of 6 signals
Market Cap
$4.5M
Cash Runway
—
Lead Asset
cvsi-007 (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for CV Sciences, Inc..
CV Sciences, Inc. is a biotechnology company focused on drug development and commercialization, with a current emphasis on cost reduction and capital raising to address a significant accumulated deficit and negative cash flow from operations.
- CV Sciences reported total revenue of $3.0M and a net loss of -$0.8M for the period ending 2026-06-30 [sec].
- As of 2026-06-30, the company held cash & equivalents of $0.3M, with shareholders' equity of $1.8M and no debt [sec].
- The company had an accumulated deficit of $87.9M as of December 31, 2025 [sec_mda · as of 2026-03-26].
- Management has implemented strategic cost reductions, including headcount cuts and reduced vendor spending, to preserve cash [sec_mda · as of 2026-03-26].
- CV Sciences faces a compliance deadline of November 13, 2026 to assess and modify product formulations in response to new legislation, which could materially impact operations [sec_mda · as of 2026-03-26].
What works
- The company has no debt as of 2026-06-30, providing financial flexibility [sec].
- Management has proactively implemented cost reductions to extend the company's cash runway [sec_mda · as of 2026-03-26].
- The company has experience in drug development and strategic alliances, as evidenced by the CFO's background [sec · filed 2025-04-15].
What to weigh
- CV Sciences has a significant accumulated deficit of $87.9M as of December 31, 2025, indicating persistent losses [sec_mda · as of 2026-03-26].
- The company generated negative cash flows from operations of $0.4M for the year ended December 31, 2025 [sec_mda · as of 2026-03-26].
- Management acknowledges dependence on additional investment capital to fund operations, with no assurance of availability on favorable terms [sec_mda · as of 2026-03-26].
- New legislation requires compliance by November 13, 2026, with potential material adverse effects on business and cash flows [sec_mda · as of 2026-03-26].
From the filings
Quoted directly from source documents.
The company had an accumulated deficit of $87.9 million as of December 31, 2025.
“we had an accumulated deficit of $87.9 million as of December 31, 2025”
SEC MD&A · March 26, 2026
The company generated negative cash flows from operations of $0.4 million for the year ended December 31, 2025.
“For the year ended December 31, 2025, we generated negative cash flows from operations of $0.4 million”
SEC MD&A · March 26, 2026
Management has implemented strategic cost reductions, including headcount and vendor spending cuts.
“Management implemented, and continues to make and implement, strategic cost reductions, including reductions in employee headcount, vendor spending”
SEC MD&A · March 26, 2026
The company has until November 13, 2026 to assess and modify product formulations due to new legislation.
“We have until November 13, 2026 to assess and, if necessary, modify our product formulations, labeling, and related compliance measures in response to this legislation”
SEC MD&A · March 26, 2026
Risks & what to watch (3)›
Key risks
- Going concern risk — Dependence on additional capital; negative cash flows and accumulated deficit of $87.9M [sec_mda · as of 2026-03-26]
- Legislative compliance deadline — Must comply by Nov 13, 2026; could materially adversely affect business and cash flows [sec_mda · as of 2026-03-26]
- Limited cash runway — Cash & equivalents only $0.3M as of 2026-06-30, with ongoing operating losses [sec]
What to watch
- Ability to raise additional capital through equity or debt markets, as management has indicated dependence on such funding [sec_mda · as of 2026-03-26].
- Progress on compliance with new legislation by the November 13, 2026 deadline and its impact on product portfolio [sec_mda · as of 2026-03-26].
- Effectiveness of ongoing cost reduction measures in preserving cash and reducing operating losses [sec_mda · as of 2026-03-26].
- Any updates on drug development activities and potential strategic alliances [sec · filed 2025-04-15].
Sources: Competitor trials · News · SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run CV Sciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CV Sciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Profitable (positive operating cash flow)
D/E 3.15 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Governance
Frequently asked questions
What is the AI investment thesis for CV Sciences, Inc.?
CV Sciences, Inc. is a biotechnology company focused on drug development and commercialization, with a current emphasis on cost reduction and capital raising to address a significant accumulated deficit and negative cash flow from operations.
What is CV Sciences, Inc.'s lead drug candidate?
CV Sciences, Inc.'s most advanced tracked candidate is cvsi-007 (Preclinical) for smokeless tobacco use and addiction.
Who is the CEO of CV Sciences, Inc.?
Mr. Joseph D. Dowling is the chief executive officer of CV Sciences, Inc. (CVSI).
Where is CV Sciences, Inc. headquartered?
CV Sciences, Inc. (CVSI) is headquartered in San Diego, CA, United States.
What therapeutic areas does CV Sciences, Inc. focus on?
CV Sciences, Inc. develops therapies across Psychiatry.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.